Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001437 · ClinicalTrials.gov registry record · Phase 2
Trial of Pentoxifylline in Patients With Functional Disability Caused by Radiation-Induced Advanced Regional Fibrosis
A Phase 2 study of Fibrosis and Radiation Injuries, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT00001437 is a Phase 2 study of Fibrosis and Radiation Injuries that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 50 participants, below the 216-participant average among 10 other Fibrosis trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00001437, a Phase 2 study of Fibrosis and Radiation Injuries, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
After initial assessment of their condition by specified clinical and laboratory parameters, each of the patients will be treated for 8 weeks at the standard pentoxifylline dose (400 mg po TID). Objective and subjective response parameters will be re-assessed at the end of the treatment and 8 weeks later for possible decay of response.
Conditions Studied
Interventions
- DRUG pentoxifylline
Study Locations (1)
Maryland
- National Cancer Institute (NCI) - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 1995-06 |
| Est. Completion | 2000-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00001437
The ClinicalTrials.gov registry entry for NCT00001437 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 216-participant average among 10 other Fibrosis trials with a reported enrollment target (77% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which pentoxifylline is the first listed.
NCT00001437 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00001437 about?
NCT00001437 is a clinical study titled "Trial of Pentoxifylline in Patients With Functional Disability Caused by Radiation-Induced Advanced Regional Fibrosis". After initial assessment of their condition by specified clinical and laboratory parameters, each of the patients will be treated for 8 weeks at the standard pentoxifylline dose (400 mg po TID). Objective and subjective response parameters will be re-assessed at the end of the treatment and 8 weeks ...
What is the current status of trial NCT00001437?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 1995-06. Estimated completion is 2000-03.
What conditions does trial NCT00001437 study?
This clinical trial studies the following conditions: Fibrosis, Radiation Injuries.
What interventions are being tested in trial NCT00001437?
The interventions under investigation include: pentoxifylline (DRUG).
Who is sponsoring clinical trial NCT00001437?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00001437 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)
RECRUITING · Phase 2
-
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
RECRUITING · Phase 2
-
Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)
RECRUITING · Phase 2
-
A Study of Mosliciguat in PH-ILD
ACTIVE NOT RECRUITING · Phase 2
-
Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis
COMPLETED · Phase 2
-
Copper Supplementation in Cirrhosis
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.